A Post-Marketing Surveillance Study to Assess Safety of Ozanimod in Patients With Moderate to Severe Active UC in Korea

Post-Marketing Surveillance (PMS) Study on Zeposia® (Ozanimod) Use Among Moderate to Severe Active Ulcerative Colitis Patients in Korea

The purpose of this observational study is to assess the real-world safety of ozanimod in Korean participants with moderate to severe active ulcerative colitis.

Inclusion Criteria:

• Adult participants 19 years of age or older
• Participants who will receive ozanimod according to the approved label after enrollment
• Participants who sign the informed consent form voluntarily

Exclusion Criteria:

• Participants who are prescribed ozanimod for therapeutic indications not approved in Korea
• Participants for whom ozanimod is contraindicated as clarified in Korean prescribing information approved by Ministry of Food and Drug Safety